Journal of Scleroderma and Related Disorders

Scope & Guideline

Advancing knowledge for a brighter future in scleroderma research.

Introduction

Explore the comprehensive scope of Journal of Scleroderma and Related Disorders through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore Journal of Scleroderma and Related Disorders in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN2397-1983
PublisherSAGE PUBLICATIONS LTD
Support Open AccessNo
CountryItaly
TypeJournal
Convergefrom 2016 to 2024
AbbreviationJ SCLERODERMA RELAT / J. Scleroderma Relat. Disord.
Frequency3 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND

Aims and Scopes

The Journal of Scleroderma and Related Disorders focuses on advancing the understanding and management of systemic sclerosis and related conditions. It serves as a platform for innovative research that spans a wide array of clinical, epidemiological, and therapeutic aspects of scleroderma.
  1. Clinical Research on Systemic Sclerosis:
    The journal prioritizes original clinical studies that investigate various manifestations of systemic sclerosis, including its impact on organs such as the lungs, heart, and gastrointestinal tract.
  2. Therapeutic Approaches and Innovations:
    Research articles often explore novel therapeutic strategies and treatment protocols, including the use of biologics, immunosuppressants, and emerging therapies tailored to scleroderma.
  3. Patient-Centered Care and Quality of Life:
    The journal emphasizes studies that assess the quality of life and patient-reported outcomes for individuals with systemic sclerosis, highlighting the importance of psychosocial factors in disease management.
  4. Epidemiological and Public Health Studies:
    There is a consistent focus on epidemiological research that addresses the prevalence, risk factors, and long-term outcomes associated with systemic sclerosis across diverse populations.
  5. Interdisciplinary Approaches:
    The journal encourages interdisciplinary research that brings together insights from various fields such as rheumatology, dermatology, cardiology, and nutrition to provide a holistic understanding of systemic sclerosis.
Recent publications in the Journal of Scleroderma and Related Disorders indicate several emerging themes that reflect the evolving landscape of research in systemic sclerosis. These trends highlight areas of growing interest and potential impact on clinical practice.
  1. Impact of COVID-19 on Systemic Sclerosis:
    An increasing number of studies address the implications of COVID-19 on the management and outcomes of patients with systemic sclerosis, emphasizing the need for adaptive care strategies during the pandemic.
  2. Nutrition and Lifestyle Interventions:
    There is a rising focus on the role of nutrition and lifestyle factors in the management of systemic sclerosis, exploring how these elements can influence disease progression and patient well-being.
  3. Digital Health and Telemedicine:
    Emerging research is examining the use of digital health technologies and telemedicine in the management of systemic sclerosis, particularly in enhancing patient access to care and improving monitoring.
  4. Mental Health and Psychosocial Factors:
    Studies increasingly explore the psychosocial dimensions of living with systemic sclerosis, including the effects of mental health on disease management and quality of life.
  5. Machine Learning and Diagnostic Innovations:
    There is a growing interest in the application of machine learning and other advanced technologies to improve the diagnosis and management of systemic sclerosis, reflecting broader trends in healthcare innovation.

Declining or Waning

While the Journal of Scleroderma and Related Disorders continues to expand its focus, certain themes appear to be declining in prominence. This trend may reflect shifts in research priorities or advancements in understanding that have influenced the scope of inquiry.
  1. Rare and Uncommon Manifestations:
    Research focusing on rare manifestations of systemic sclerosis, such as specific types of skin involvement or rare comorbidities, has decreased. This may indicate a shift towards more prevalent and impactful aspects of the disease.
  2. Historical Perspectives and Case Reports:
    There has been a noticeable reduction in the publication of historical case reports and vignettes, suggesting a possible move towards more data-driven, clinical, and experimental research.
  3. Basic Science Research:
    The journal has seen a waning interest in basic science studies that do not directly translate to clinical implications, possibly due to a growing emphasis on translational research that bridges bench to bedside.

Similar Journals

Neurology and Therapy

Empowering Practitioners with the Latest in Neurology and Therapy
Publisher: SPRINGER LONDON LTDISSN: 2193-8253Frequency: 2 issues/year

Neurology and Therapy, published by SPRINGER LONDON LTD, stands as a pivotal platform for researchers and practitioners in the field of neurology and its therapeutic applications. This Open Access journal, active since 2012, facilitates the dissemination of innovative studies and cutting-edge findings aimed at improving neurological health. With an impressive ranking in the 2023 Scopus Rankings, where it holds a Q2 category in Neurology and a Q1 category in Clinical Neurology, it underscores its prominence in advancing neurological research. The journal's intriguing scope encompasses a wide-ranging exploration of neurological disorders, treatment methodologies, and healthcare strategies, making it a valuable resource for those vested in enhancing patient outcomes. With an appealing average impact factor, readers are encouraged to dive into the latest advancements and engage with the scholarly discussions that are shaping the future of neurology.

LANCET NEUROLOGY

Shaping the Future of Neurological Care
Publisher: ELSEVIER SCIENCE INCISSN: 1474-4422Frequency: 12 issues/year

The Lancet Neurology is a premier academic journal published by Elsevier Science Inc, specializing in the field of neurology. With a robust impact factor that signifies its authoritative presence, it consistently ranks in the Q1 category for clinical neurology according to the 2023 standards, positioning itself as the leading journal in its domain, ranking #1 out of 400 in Scopus' neurology rankings and placing in the 99th percentile. Since its establishment in 2002, it has provided a vital platform for disseminating innovative research and clinical advances related to neurological disorders. The journal’s precise focus includes cutting-edge studies on neurodegenerative diseases, stroke, epilepsy, and neuroimaging, which are essential for advancing clinical practice and improving patient outcomes. While it does not offer open access, readers can find high-impact research published monthly, making it indispensable for practitioners, researchers, and students eager to stay at the forefront of neurological science.

RHEUMATOLOGY INTERNATIONAL

Elevating the standards of rheumatological science.
Publisher: SPRINGER HEIDELBERGISSN: 0172-8172Frequency: 12 issues/year

Rheumatology International, published by Springer Heidelberg, is a prestigious journal that focuses on innovative research in the field of rheumatology and immunology. Established in 1981, this peer-reviewed journal has contributed significantly to advancing our understanding of autoimmune disorders, clinical approaches, and therapeutic interventions. It holds a commendable Q2 ranking in the categories of Immunology, Immunology and Allergy, and Rheumatology as of 2023, showcasing its influence and importance within these disciplines. With a robust Scopus ranking—positioned 14 out of 73 in Medicine Rheumatology—it caters to a diverse audience of researchers, clinicians, and students committed to improving patient care and treatment modalities. Although it does not currently offer open access options, the journal remains a vital resource for insights on contemporary challenges and breakthroughs in rheumatological research, published from its base in Heidelberg, Germany.

Multiple Sclerosis International

Advancing knowledge, transforming lives in MS research.
Publisher: HINDAWI LTDISSN: 2090-2654Frequency:

Multiple Sclerosis International is a leading open-access journal dedicated to advancing the scientific understanding of multiple sclerosis (MS) and related neurological disorders. Published by HINDAWI LTD since 2010, this journal serves as a vital resource for researchers, clinicians, and students alike, providing a platform for high-quality peer-reviewed articles that cover a diverse range of topics, including epidemiology, treatment strategies, and the latest advancements in MS research. With its commitment to open access, Multiple Sclerosis International ensures that critical findings are readily available to the global community, fostering collaborative efforts to improve patient outcomes and advance therapeutic approaches. The journal not only enhances scholarly discourse in the field but also significantly impacts clinical practices by presenting cutting-edge research and insights.

Therapeutic Advances in Neurological Disorders

Pioneering insights for the treatment of neurological disorders.
Publisher: SAGE PUBLICATIONS LTDISSN: 1756-2856Frequency: 1 issue/year

Therapeutic Advances in Neurological Disorders, published by SAGE Publications Ltd, is a leading open access journal dedicated to the advancement of knowledge in the field of neurology. Since its inception in 2008, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for the dissemination of high-quality research that improves the understanding and treatment of neurological disorders. With a commendable impact factor and ranked Q1 in multiple categories, including Neurology and Pharmacology for 2023, it exemplifies excellence in scholarly contributions. The journal's Scope encompasses a wide array of topics, providing insights that are pivotal for clinical practice and pharmacological development. Additionally, with its commitment to open access since 2017, Therapeutic Advances in Neurological Disorders ensures that its research reaches a global audience, fostering collaboration and innovation in neurological science.

Reumatologia Clinica

Exploring breakthroughs in clinical rheumatology.
Publisher: ELSEVIER ESPANA SLUISSN: 1699-258XFrequency: 6 issues/year

Reumatologia Clinica is a distinguished journal dedicated to the field of Rheumatology, published by Elsevier España SLU. With its ISSN of 1699-258X and E-ISSN 1885-1398, the journal aims to disseminate pivotal research findings and clinical studies from 2005 to 2024, spotlighting advancements in the understanding and treatment of rheumatic diseases. Based in Barcelona, Spain, it plays a vital role in the academic community, ranking in the Q3 category for Rheumatology as of 2023, with a Scopus ranking of #44 out of 73, placing it in the 40th percentile. Although it operates under a traditional access model, the journal is committed to academic excellence, providing researchers, healthcare professionals, and students with invaluable insights that drive the field forward. Reumatologia Clinica serves as an essential resource for those looking to deepen their knowledge and contribute to the evolving landscape of rheumatologic research.

JOURNAL OF RHEUMATOLOGY

Leading the Way in Rheumatology and Immunology Advancements
Publisher: J RHEUMATOL PUBL COISSN: 0315-162XFrequency: 12 issues/year

JOURNAL OF RHEUMATOLOGY, published by the J Rheumatol Publ Co, stands as a distinguished platform within the fields of rheumatology and immunology since its inception in 1974. With an impressive impact evidenced by its 2023 rankings—Q1 in Rheumatology and Q2 in both Immunology and Allergy—the journal has secured its position as a vital resource for researchers and practitioners alike. The journal is dedicated to advancing clinical and experimental knowledge in the pathogenesis, diagnosis, and management of rheumatic diseases, providing a rich repository of peer-reviewed articles that drive innovation in treatment protocols and patient care. Although it operates under a subscription model, the journal remains accessible to a broad audience committed to advancing their understanding of these critical areas. Located in Toronto, Canada, it continues to attract contributions from leading experts globally, making it an essential read for anyone keen on staying at the forefront of rheumatological research and practice.

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Elevating Dermatological Research to New Heights
Publisher: ADIS INT LTDISSN: 1175-0561Frequency: 6 issues/year

The American Journal of Clinical Dermatology, published by Adis International Ltd, is a leading peer-reviewed journal dedicated to advancing the field of dermatology. With a notable impact factor and a prestigious Q1 rank in both Dermatology and Miscellaneous Medicine categories, this journal stands out as a valuable resource for researchers and clinicians alike, offering cutting-edge insights into clinical practice and innovative treatment strategies. Its comprehensive scope encompasses a broad range of topics within dermatology, addressing both common and rare conditions, with a focus on emerging therapies and technologies. As it converges its publication years from 2000 to 2024, the journal remains an essential platform for disseminating high-quality research to professionals striving to improve patient care and outcomes. With the ISSN 1175-0561 and E-ISSN 1179-1888, the American Journal of Clinical Dermatology facilitates greater accessibility to pivotal findings within the field, making it an indispensable resource for anyone involved in dermatological research and practice.

NEUROLOGY

Unveiling the latest innovations in brain health.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0028-3878Frequency: 48 issues/year

NEUROLOGY, published by Lippincott Williams & Wilkins, stands as a premier journal in the field of neurology, holding an esteemed Q1 category ranking in clinical neurology as of 2023. Established in 1951, this journal has been a critical resource for the dissemination of cutting-edge research and clinical advancements, with an impressive Scopus rank of 24 out of 400, placing it in the 94th percentile among its peers. NEUROLOGY serves as a vital platform for neurologists, researchers, and medical professionals seeking to stay abreast of the latest findings and innovations in the treatment and understanding of neurological disorders. With its rigorous peer-review process and commitment to excellence, NEUROLOGY remains essential reading for all individuals dedicated to advancing the science and practice of neurology, contributing significantly to the ongoing dialogue in this vital area of medicine.

Current Rheumatology Reviews

Pioneering insights for modern rheumatology.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1573-3971Frequency: 3 issues/year

Current Rheumatology Reviews is an esteemed journal dedicated to publishing comprehensive reviews on advancements in the field of rheumatology. Established by Bentham Science Publishers, this journal has become a vital resource for researchers, clinicians, and students seeking to stay abreast of the latest developments and therapeutic strategies from 2006 to 2024. Located in the United Arab Emirates, it caters to a global audience, delivering insights that have been pivotal in shaping clinical practices. With an impact factor reflective of its Q3 status in Rheumatology by 2023, the journal ranks #46 out of 73 in the Scopus database, positioning it in the 37th percentile in the discipline. Although it operates without open access, its high-quality content ensures that each article undergoes rigorous peer review, making the Current Rheumatology Reviews a trusted platform for disseminating critical research findings and reviews that drive forward the understanding and treatment of rheumatic diseases.